ABBV-400 for Advanced Solid Tumors
What is the Purpose of this Study?
If you choose to join this study, you will:
- Get IV infusions of the study drug every 3 weeks for up to 2 years
- Give blood and urine samples
- Have regular CT or MRI scans
- Get IV infusions of the study drug every 3 weeks for up to 2 years
- Give blood and urine samples
- Have regular CT or MRI scans
What is the Condition Being Studied?
Advanced Solid Tumors
Who Can Participate in this Study?
Adults ages 18+ who:
- Are diagnosed with an advanced form of cancer
- Have not seen improvement from standard therapies
For more information about who can join this study, please contact the study team at 919-668-1861.
Age Group
Adults
Participating Institutions
What is Involved?
We are doing this study to find the best dose of the study drug, ABBV-400, and to see if it is a safe and effective option for treating cancer.
Study Details
Full Title
[M21-404] A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 in adult subjects with advanced solid tumors
Principal Investigator
Contacts
Gastrointestinal Oncology DCI Clinical Research Team
Email: gi-oncology-cru@dm.duke.edu
Phone: +1 919-668-1861
Protocol Number
IRB:
PRO00111582
NCT:
NCT05029882
ClinicalTrials.gov
View on ClinicalTrials.gov